PolyPid Ltd. (PYPD)

Market Cap	28.33M
Revenue (ttm)	n/a
Net Income (ttm)	-30.84M
Shares Out	10.19M
EPS (ttm)	-4.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,092
Open	2.825
Previous Close	2.790
Day's Range	2.754 - 2.830
52-Week Range	2.300 - 4.670
Beta	1.26
Analysts	Strong Buy
Price Target	10.50 (+277.7%)
Earnings Date	May 14, 2025

About PYPD

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2020
• Employees: 60
• Stock Exchange: NASDAQ
• Ticker Symbol: PYPD
• Website: https://www.polypid.com

Analyst Forecast

According to 2 analysts, the average rating for PYPD stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 277.70% from the latest price.

Price Target

$10.5

(277.70% upside)

Analyst Consensus: Strong Buy